Esperion Therapeutis.Inc. buy dartajon99
Summary
This prediction ended on 23.06.23 with a price of €1.26. The prediction for Esperion Therapeutis.Inc. disappointed with a performance of -17.49%. dartajon99 has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Esperion Therapeutis.Inc. | -3.717% | -3.717% | 65.564% |
iShares Core DAX® | -3.033% | 0.651% | 12.268% |
iShares Nasdaq 100 | -3.554% | -3.007% | 27.682% |
iShares Nikkei 225® | -3.938% | 1.935% | 10.515% |
iShares S&P 500 | -1.517% | -0.602% | 25.859% |
According to dartajon99 what are the pros and cons of Esperion Therapeutis.Inc. for the foreseeable future?
Pros
Cons
Comments by dartajon99 for this prediction
In the thread Trading Esperion Therapeutis.Inc.